News
2h
MarketBeat on MSNIs Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...
Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...
Shares of Eli Lilly (LLY -2.90%) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...
1h
Zacks Investment Research on MSNHIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin DownHims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 20 cents in first-quarter 2025 compared with the ...
The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide), a once-weekly GLP-1 drug that is the market leader in the class with sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results